Timothy J. Henkel
Directeur Technique/Scientifique/R&D chez Vicuron Pharmaceuticals LLC
Profil
Timothy J.
Henkel is currently a Director at Palvella Therapeutics, Inc. and the Chief Medical Officer at Vicuron Pharmaceuticals LLC.
He previously held positions as Vice President-Clinical Development at Smithkline Beecham Plc, Executive VP, Head-Research & Development at Ceptaris Therapeutics, Inc., and Executive Vice President-Research & Development at Ception Therapeutics, Inc. He also worked as an Assistant Professor at the University of Washington.
Henkel received his doctorate from the University of Washington in 1988 and his undergraduate degree from Rhodes College in 1981.
Postes actifs de Timothy J. Henkel
| Sociétés | Poste | Début |
|---|---|---|
Vicuron Pharmaceuticals LLC
 Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA. | Directeur Technique/Scientifique/R&D | - |
Palvella Therapeutics, Inc.
 Palvella Therapeutics, Inc. BiotechnologyHealth Technology Palvella Therapeutics, Inc. operates as a rare disease biopharmaceutical company. It develops and commercializes pathogenetically targeted therapies for rare genodermatoses with no approved treatments. Its products include QTORIN, PTX-022, PTX-367, and PTX-014. The company was founded by Wesley H. Kaupinen in 2015 and is headquartered in Wayne, PA. | Directeur/Membre du Conseil | - |
Anciens postes connus de Timothy J. Henkel
| Sociétés | Poste | Fin |
|---|---|---|
Ceptaris Therapeutics, Inc.
 Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | Directeur Technique/Scientifique/R&D | - |
Smithkline Beecham Plc
 Smithkline Beecham Plc Pharmaceuticals: OtherHealth Technology Smithkline Beecham Plc develops and manufactures pharmaceutical products. The company markets pharmaceuticals for human and animal healthcare consumption, vaccines, over the counter medicines, health related consumer products, clinical laboratory testing services, disease management and pharmaceutical benefit management. It is headquartered in Brentford, UK. | Corporate Officer/Principal | - |
University of Washington
 University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | Corporate Officer/Principal | - |
Ception Therapeutics, Inc.
 Ception Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ception Therapeutics, Inc. Develops pharmaceutical products. It focuses on the discovery and development of novel products to address areas of unmet medical need. The company was founded in 2004 and is headquartered in Malvern, PA. | Directeur Technique/Scientifique/R&D | - |
Formation de Timothy J. Henkel
| University of Washington | Doctorate Degree |
| Rhodes College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Vicuron Pharmaceuticals LLC
Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA. | Health Technology |
Ception Therapeutics, Inc.
Ception Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ception Therapeutics, Inc. Develops pharmaceutical products. It focuses on the discovery and development of novel products to address areas of unmet medical need. The company was founded in 2004 and is headquartered in Malvern, PA. | Health Technology |
Smithkline Beecham Plc
Smithkline Beecham Plc Pharmaceuticals: OtherHealth Technology Smithkline Beecham Plc develops and manufactures pharmaceutical products. The company markets pharmaceuticals for human and animal healthcare consumption, vaccines, over the counter medicines, health related consumer products, clinical laboratory testing services, disease management and pharmaceutical benefit management. It is headquartered in Brentford, UK. | Health Technology |
Ceptaris Therapeutics, Inc.
Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | Health Technology |
Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc. BiotechnologyHealth Technology Palvella Therapeutics, Inc. operates as a rare disease biopharmaceutical company. It develops and commercializes pathogenetically targeted therapies for rare genodermatoses with no approved treatments. Its products include QTORIN, PTX-022, PTX-367, and PTX-014. The company was founded by Wesley H. Kaupinen in 2015 and is headquartered in Wayne, PA. | Health Technology |